Screening and characterization of vaginal fluid donations for vaginal microbiota transplantation.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 10 2022
26 10 2022
Historique:
received:
03
03
2022
accepted:
20
10
2022
entrez:
26
10
2022
pubmed:
27
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Bacterial vaginosis (BV), the overgrowth of diverse anaerobic bacteria in the vagina, is the most common cause of vaginal symptoms worldwide. BV frequently recurs after antibiotic therapy, and the best probiotic treatments only result in transient changes from BV-associated states to "optimal" communities dominated by a single species of Lactobacillus. Therefore, additional treatment strategies are needed to durably alter vaginal microbiota composition for patients with BV. Vaginal microbiota transplantation (VMT), the transfer of vaginal fluid from a healthy person with an optimal vaginal microbiota to a recipient with BV, has been proposed as one such alternative. However, VMT carries potential risks, necessitating strict safety precautions. Here, we present an FDA-approved donor screening protocol and detailed methodology for donation collection, storage, screening, and analysis of VMT material. We find that Lactobacillus viability is maintained for over six months in donated material stored at - 80 °C without glycerol or other cryoprotectants. We further show that species-specific quantitative PCR for L. crispatus and L. iners can be used as a rapid initial screening strategy to identify potential donors with optimal vaginal microbiomes. Together, this work lays the foundation for designing safe, reproducible trials of VMT as a treatment for BV.
Identifiants
pubmed: 36289360
doi: 10.1038/s41598-022-22873-y
pii: 10.1038/s41598-022-22873-y
pmc: PMC9606370
doi:
Substances chimiques
Glycerol
PDC6A3C0OX
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17948Subventions
Organisme : NIAID NIH HHS
ID : R01 AI158836
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2019 Oct;25(10):1500-1504
pubmed: 31591599
Clin Diagn Lab Immunol. 2001 Sep;8(5):955-8
pubmed: 11527810
Front Cell Infect Microbiol. 2019 Aug 28;9:306
pubmed: 31555606
Gastroenterol Hepatol (N Y). 2017 Apr;13(4):209-213
pubmed: 28546791
J Infect Dis. 2021 Jun 16;223(12 Suppl 2):S276-S282
pubmed: 33330910
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
Lancet Infect Dis. 2018 May;18(5):554-564
pubmed: 29396006
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Nucleic Acids Res. 2014 Jan;42(Database issue):D633-42
pubmed: 24288368
BJOG. 2020 Jan;127(2):287-299
pubmed: 31299136
PLoS One. 2013 Dec 20;8(12):e82599
pubmed: 24376552
Trends Microbiol. 2017 Mar;25(3):182-191
pubmed: 27914761
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
N Engl J Med. 2020 May 14;382(20):1906-1915
pubmed: 32402161
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
J Clin Microbiol. 2011 Aug;49(8):3029-32
pubmed: 21632892
J Clin Microbiol. 2009 Mar;47(3):721-6
pubmed: 19144794
J Womens Health (Larchmt). 2009 Nov;18(11):1817-24
pubmed: 19951217
Immunity. 2017 Jan 17;46(1):29-37
pubmed: 28087240
J Forensic Leg Med. 2013 Nov;20(8):1126-30
pubmed: 24237835
Microbiome. 2018 Dec 10;6(1):220
pubmed: 30526683
Sex Transm Dis. 2020 Jul;47(7):441-446
pubmed: 32235174
Microbiome. 2021 Jul 26;9(1):163
pubmed: 34311774
Sex Transm Dis. 2019 May;46(5):304-311
pubmed: 30624309
Am J Obstet Gynecol. 2020 Feb;222(2):157.e1-157.e13
pubmed: 31404542
PLoS One. 2010 Apr 15;5(4):e10197
pubmed: 20419168